Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight
A J
AJ
Northern Ireland Public Health Laboratory, Department of Bacteriology, Belfast City Hospital, Northern Ireland.
Shaw
A
A
Goldsmith
C E
CE
Clarke
L
L
Millar
B C
BC
McCaughan
J
J
Elborn
J S
JS
Reid
A
A
Moore
J E
JE
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods; D015242:Ofloxacin / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D020615:Stenotrophomonas maltophilia / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin